Showing 1 - 10 of 858
Patents have long been regarded as the 'gold standard' of intellectual property protection. In 'Little patents and big secrets: managing intellectual property', Anton and Yao (2004) call this traditional view into question by finding that firms keep their most important innovations secret. This...
Persistent link: https://www.econbiz.de/10010294701
Patents have long been regarded as the 'gold standard' of intellectual property protection. In "Little patents and big secrets: managing intellectual property", Anton and Yao (2004) call this traditional view into question by finding that firms keep their most important innovations secret. This...
Persistent link: https://www.econbiz.de/10009313608
We investigate whether patents that are jointly held by legally independent companies help sustain product-market collusion. We use a simple model of repeated interactions to show that joint patents can serve collusive purposes. Our model generates two testable predictions: when joint patents...
Persistent link: https://www.econbiz.de/10009791540
This paper utilizes a data set of over 208,000 U.S. patents applied for between 1975 and 2010 to study development of strategic patenting over time and across industries. With received citations as a measure of patent social value, we use data envelopment analysis to estimate firm-level relative...
Persistent link: https://www.econbiz.de/10011456844
This paper analyses the causal impact of Intellectual Property Rights (IPR) on pharmaceutical innovation in a panel of 74 countries. The identification strategy exploits the different timing across countries of two sets of IPR reforms. Domestic innovation is measured as citation-weighted...
Persistent link: https://www.econbiz.de/10011509446
Patents should no longer be granted for DNA, but only for new medicinal products, new vaccines and genetic tests which are developed on the basis of DNA. Only in this way, patent law can gain general acceptance in civil and academic society, without losing sight of the interests of the biotech...
Persistent link: https://www.econbiz.de/10013115440
This report provides the first edition of a European patent indicator for access to genetic resources and benefit-sharing developed for the European Environment Agency as part of the Streamlining European Biodiversity Indicators (SEBI 2010) process (Report EEA/BSS/08/012). The patent indicator...
Persistent link: https://www.econbiz.de/10013095961
The Italian and European regulatory framework for patents would benefit from further improvements in order to foster dynamic competition between Italian firms. At the national level the exclusive allocation of the right to patent inventions to universities, rather than to researchers, would...
Persistent link: https://www.econbiz.de/10013109093
We compare patent litigation cases across four European jurisdictions – Germany, France, the Netherlands, and the UK – covering cases filed during the period 2000-2008. For our analysis, we assemble a new dataset that contains detailed information at the case, litigant, and patent level for...
Persistent link: https://www.econbiz.de/10013075267
As an economist, I find the current state of the law regarding damages for patent infringement – most particularly that relating to apportionment – frustrating at best and woefully incomplete at worst. Namely, damages case law for utility patent infringement provides two very different, but...
Persistent link: https://www.econbiz.de/10012963876